© 2021 MJH Life Sciences and HCPLive. All rights reserved.
© 2021 MJH Life Sciences™ and HCPLive. All rights reserved.
December 23, 2020
Fewer patients who received masitinib 4.5 mg/kg/day reached severe dementia stage.
December 11, 2020
Researchers from USC propose a direct neurotoxic effect of particulate matter smaller than 2.5 μm.
December 08, 2020
After a sudden reversal and complex analyses, aducanumab’s future rests in the hands of the FDA while the community stands split on if the available data are enough to justify an approval.
November 06, 2020
AXS-05 significantly relieved agitation, demonstrating a change from baseline in the CMAI total score of 15.4 compared to 11.5 for the placebo.
October 23, 2020
The findings of this multicenter cohort may have implications for diagnosis, prognosis, and disease monitoring, as well as for clinical trials targeting disease-specific proteins in DLB.
September 25, 2020
The treatment could also be used for Alzheimer disease and mid-stage Huntington disease for patients who suffer from greater cognitive deficits.
September 19, 2020
Sumifilam could be the first Alzheimer treatment to improve several biomarkers.
August 10, 2020
A team of researchers have added 3 new modifiable risk factors to a list of 9 known factors that increase the risk of developing dementia.
An expert in Alzheimer disease describes some of the struggles dementia patients might be going through during the COVID-19 pandemic.
August 07, 2020
Investigators found a 22% reduction in clinical decline at the 78-week cutoff in the intent to treat population in EMERGE who received high-dose aducanumab, with a similar reduction seen in the opportunity to complete population.